Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed Duration vs Continuous Anti-CD38 Therapy in Transplant-Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
NCT06182774Phase 3Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Apr 2024
- Primary completion
- Jan 2032
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab, isatuximab in multiple myeloma (MM), sponsored by Canadian Cancer Trials Group. Started Apr 2024; status: recruiting.
02
Drugs
daratumumabisatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06182774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182774.